Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

Anterior chamber migration of dexametasone intravitreal implant (Ozurdex®). Graefes Arch Clin Exp Ophthalmol (2011) 1.54

Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol (2011) 1.46

Ocular complications of diabetes mellitus. World J Diabetes (2015) 1.27

Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema. Clin Ophthalmol (2013) 1.17

Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant. Clin Ophthalmol (2010) 1.16

Intravitreal steroids for the treatment of retinal diseases. ScientificWorldJournal (2014) 1.05

Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol (2015) 1.05

Efficacy of Ozurdex implant in recalcitrant diabetic macular edema-a single-center experience. Int Ophthalmol (2015) 1.03

Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open (2013) 1.00

Economic considerations of macular edema therapies. Ophthalmology (2011) 0.96

Treatment of macular edema due to retinal vein occlusions. Clin Ophthalmol (2011) 0.95

Vascular complications and diabetes: current therapies and future challenges. J Ophthalmol (2012) 0.95

Current trends in the monitoring and treatment of diabetic retinopathy in young adults. Mediators Inflamm (2014) 0.95

A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye (Lond) (2015) 0.92

Microvascular complications and diabetic retinopathy: recent advances and future implications. Future Med Chem (2013) 0.92

Diabetic macular edema: current and emerging therapies. Middle East Afr J Ophthalmol (2012) 0.90

Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema. Drug Des Devel Ther (2013) 0.89

Ozurdex (a slow-release dexamethasone implant) in proliferative vitreoretinopathy: study protocol for a randomised controlled trial. Trials (2013) 0.88

Emerging pharmacotherapies for diabetic macular edema. Exp Diabetes Res (2012) 0.86

Diabetic macular edema: New promising therapies. World J Diabetes (2013) 0.85

Intravitreal Injection of Ozurdex(®) Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up. Ophthalmol Eye Dis (2016) 0.85

The evolving treatment options for diabetic macular edema. Int J Inflam (2013) 0.83

Efficacy and safety of different doses of a slow-release corticosteroid implant for macular edema: meta-analysis of randomized controlled trials. Drug Des Devel Ther (2015) 0.83

Efficacy and tolerability of bilateral sustained-release dexamethasone intravitreal implants for the treatment of noninfectious posterior uveitis and macular edema secondary to retinal vein occlusion. Clin Ophthalmol (2015) 0.82

Clinical trials on corticosteroids for diabetic macular edema. World J Diabetes (2013) 0.81

Intravitreal Corticosteroids in the Management of Diabetic Macular Edema. Curr Ophthalmol Rep (2013) 0.81

Morphology and Function over a One-Year Follow Up Period after Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema. PLoS One (2015) 0.81

[Intravitreal implants: drug carriers and carriers of hope?]. Ophthalmologe (2011) 0.80

Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management. Ophthalmol Ther (2016) 0.80

Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2014) 0.80

Short-term safety and efficacy of intravitreal 0.7-mg dexamethasone implants for pseudophakic cystoid macular edema. Saudi J Ophthalmol (2014) 0.80

Influence of permeant lipophilicity on permeation across human sclera. Pharm Res (2010) 0.80

Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema. World J Diabetes (2013) 0.79

Diabetic macular edema: therapeutic options. Diabetes Ther (2012) 0.78

Efficacy and Safety of a Dexamethasone Implant in Patients with Diabetic Macular Edema at Tertiary Centers in Korea. J Ophthalmol (2016) 0.77

Efficacy of single-dose dexamethasone implantation in patients with persistent diabetic macular edema. Int Ophthalmol (2015) 0.77

An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol (2016) 0.77

INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: Pharmacokinetic Considerations. Retina (2015) 0.77

Updates on the Clinical Trials in Diabetic Macular Edema. Middle East Afr J Ophthalmol (2016) 0.77

Review of therapeutic advances in diabetic retinopathy. Ther Adv Endocrinol Metab (2011) 0.77

Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections. Eye (Lond) (2016) 0.76

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema. Clin Ophthalmol (2016) 0.75

OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT. Retina (2016) 0.75

Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant. Diabetes Metab Syndr Obes (2015) 0.75

Diabetic Retinopathy Clinical Practice Guidelines: Customized for Iranian Population. J Ophthalmic Vis Res (2016) 0.75

Twelve-Month Results of a Single or Multiple Dexamethasone Intravitreal Implant for Macular Edema following Uncomplicated Phacoemulsification. Biomed Res Int (2015) 0.75

Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials. Br J Ophthalmol (2015) 0.75

Vitrectomy for diabetic macular edema; where are we? J Curr Ophthalmol (2016) 0.75

Diabetic retinopathy (treatment). BMJ Clin Evid (2011) 0.75

Phacoemulsification and intraocular lens implantation after inadvertent intracapsular injection of intravitreal dexamethasone implant. BMJ Case Rep (2012) 0.75

Comparison of dexamethasone intravitreal implant and intravitreal triamcinolone acetonide for the treatment of pseudophakic cystoid macular edema in diabetic patients. Drug Des Devel Ther (2014) 0.75

Efficacy and Safety of Intravitreal Dexamethasone Implants for Treatment of Refractory Diabetic Macular Edema. Korean J Ophthalmol (2017) 0.75

Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema. Clin Ophthalmol (2013) 0.75

Simultaneous dexamethasone intravitreal implant and anti-VEGF therapy for neovascular age-related macular degeneration resistant to anti-VEGF monotherapy. J Vitreoretin Dis (2017) 0.75

Comparison of early dexamethasone retreatment versus standard dexamethasone regimen combined with PRN ranibizumab in diabetic macular edema. Int Ophthalmol (2016) 0.75

Comparison of vitrectomized with nonvitrectomized eyes after subtenon injection of triamcinolone acetonide to treat diabetic macular edema: Retrospective comparative Analysis of an interventional case series. Indian J Ophthalmol (2017) 0.75

[Intravitreal dexamethasone implant for treatment of persistent postoperative macular edema after vitrectomy]. Ophthalmologe (2016) 0.75

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology (2010) 7.30

Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology (2011) 4.61

A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol (2003) 4.52

Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol (2011) 3.63

Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina (2011) 3.04

Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol (2007) 2.53

Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 2.53

The sensitivity and specificity of single-field nonmydriatic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: a comparison with ophthalmoscopy and standardized mydriatic color photography. Am J Ophthalmol (2002) 2.50

In-the-bag intraocular lens dislocation. Am J Ophthalmol (2004) 2.27

A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum (2005) 2.20

Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology (2004) 2.19

Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci (2002) 2.19

Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol (2006) 2.10

SMARTPHONE-BASED DILATED FUNDUS PHOTOGRAPHY AND NEAR VISUAL ACUITY TESTING AS INEXPENSIVE SCREENING TOOLS TO DETECT REFERRAL WARRANTED DIABETIC EYE DISEASE. Retina (2016) 2.01

Transvitreal fibrinoid pseudoendophthalmitis after diabetic vitrectomy. Retina (2013) 1.97

Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology (2003) 1.96

INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY. Retina (2016) 1.92

Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology (2002) 1.78

Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol (2003) 1.74

Imaging pulsatile retinal blood flow in human eye. J Biomed Opt (2008) 1.73

Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol (2002) 1.71

Giant macular hole in Alport syndrome. Ophthalmic Genet (2010) 1.70

One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol (2002) 1.70

The chick chorioallantoic membrane as a model tissue for surgical retinal research and simulation. Retina (2004) 1.69

Photodynamic therapy using verteporfin for choroidal neovascularization in angioid streaks. Am J Ophthalmol (2003) 1.69

Effect of pulse duration on size and character of the lesion in retinal photocoagulation. Arch Ophthalmol (2008) 1.64

Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol (2009) 1.64

Femtosecond laser capsulotomy. J Cataract Refract Surg (2011) 1.60

Sutureless scleral fixation of intraocular lenses: outcomes of two approaches. The 2014 Yasuo Tano Memorial Lecture. Graefes Arch Clin Exp Ophthalmol (2014) 1.59

Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema. Retina (2010) 1.56

Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. Arch Ophthalmol (2002) 1.53

Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology (2013) 1.52

Single-field fundus photography for diabetic retinopathy screening: a report by the American Academy of Ophthalmology. Ophthalmology (2004) 1.50

A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology (2003) 1.48

Femtosecond laser-assisted cataract surgery with integrated optical coherence tomography. Sci Transl Med (2010) 1.47

Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A (2011) 1.47

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology (2005) 1.47

Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol (2011) 1.46

LAP-BAND for lower BMI: 2-year results from the multicenter pivotal study. Obesity (Silver Spring) (2013) 1.46

Sutureless 23-gauge versus 20-gauge vitrectomy with silicone oil injection in rhegmatogenous retinal detachment. Retina (2012) 1.46

Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci (2011) 1.46

Healing of retinal photocoagulation lesions. Invest Ophthalmol Vis Sci (2008) 1.44

The challenge of determining aqueous contamination rate in anterior segment intraocular surgery. Am J Ophthalmol (2004) 1.43

Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization. Retina (2003) 1.41

The use of best visual acuity over several encounters as an outcome variable: an analysis of systematic bias. Invest Ophthalmol Vis Sci (2010) 1.39

Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology (2012) 1.32

Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. Am J Ophthalmol (2007) 1.26

Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma (2008) 1.26

Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina (2006) 1.25

Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol (2003) 1.24

Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology (2005) 1.22

Antibiotic susceptibility of preoperative normal conjunctival bacteria. Am J Ophthalmol (2005) 1.21

Vitreomacular traction syndrome: impact of anatomical configuration on anatomical and visual outcomes. Retina (2008) 1.18

Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17

Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci (2006) 1.17

Photoacoustic ocular imaging. Opt Lett (2010) 1.16

Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci (2006) 1.16

Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina (2014) 1.15

Cytokine and chemokine levels in tears from healthy subjects. Acta Ophthalmol (2010) 1.14

Localized chemical release from an artificial synapse chip. Proc Natl Acad Sci U S A (2004) 1.14

Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol (2009) 1.13

Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology (2004) 1.13

Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol (2004) 1.11

The effect of duration of macular detachment on results after the scleral buckle repair of primary, macula-off retinal detachments. Ophthalmology (2002) 1.09

Postoperative vancomycin-resistant Enterococcus faecium endophthalmitis. Arch Ophthalmol (2007) 1.09

Ranibizumab. Nat Rev Drug Discov (2006) 1.08

Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina (2009) 1.07

Trypan blue: effect on retinal pigment epithelial and neurosensory retinal cells. Invest Ophthalmol Vis Sci (2005) 1.07

Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology (2004) 1.07

Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 1.06

Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther (2005) 1.06

The Artificial Synapse Chip: a flexible retinal interface based on directed retinal cell growth and neurotransmitter stimulation. Artif Organs (2003) 1.06